Quincy Chu
Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma.
Overview
Quincy Chu is a medical oncologist at the Cross Cancer Institute in Edmonton and a thoracic disease site leader in the Canadian Cancer Trials Group. He was first author of the 2023 Lancet report of IND.227/KEYNOTE-483, the international phase 3 trial in which pembrolizumab plus platinum-pemetrexed chemotherapy improved overall survival compared with chemotherapy alone in untreated unresectable pleural mesothelioma, leading to the combination's approval.
Similar pages
not linked directly; found by shared links- PersonPaul Baas
Shares the tags mesothelioma, immunotherapy.
- TrialIND.227 / KEYNOTE-483
Shares KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma, Pleural mesothelioma.
- PersonAnna K. Nowak
Shares the tags mesothelioma, immunotherapy.
- PersonBrian I. Rini
Shares the tags immunotherapy, trialist.
- PersonCaroline Robert
Shares the tags immunotherapy, trialist.
- PersonJean-Pascal Machiels
Shares the tags immunotherapy, trialist.
- PersonJedd D. Wolchok
Shares the tags immunotherapy, trialist.
- PersonJong-Mu Sun
Shares the tags immunotherapy, trialist.